Several other analysts have also recently commented on the company. ValuEngine upgraded BioScrip from a sell rating to a hold rating in a report on Wednesday, October 2nd. Canaccord Genuity lifted their price target on BioScrip from $3.50 to $4.00 and gave the company a buy rating in a report on Thursday, August 8th. Finally, SunTrust Banks lifted their price target on BioScrip from $3.25 to $4.25 and gave the company a buy rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $4.63.
Shares of NASDAQ BIOS traded down $0.07 during trading on Friday, hitting $3.59. 894,600 shares of the company were exchanged, compared to its average volume of 1,109,970. The company has a market cap of $484.43 million, a price-to-earnings ratio of -7.33 and a beta of 0.49. The firm’s fifty day moving average price is $3.46 and its 200 day moving average price is $2.81. BioScrip has a 1 year low of $1.56 and a 1 year high of $4.14.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Further Reading: What does a bar chart display?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.